DexCom names Jake Leach as new CEO

Dexcom (DXCM) “also announced the promotion of Jake Leach to CEO and to the Dexcom Board of Directors, effective January 1, 2026. Current CEO Kevin Sayer will continue to work closely with Jake during the transition period and will remain executive chairman of the board of directors at the point of transition. Mr. Leach has helped steer the company’s biosensing platforms since the launch of its first commercial system. He has held roles of increasing responsibility across his 21-year tenure with the company. He served as executive vice president and chief technology officer from 2018 through 2022, transitioning to executive vice president and chief operating officer in late 2022. In May 2025, he was promoted to the expanded role of president and chief operating officer, assuming the additional responsibility of oversight for the company’s strategy and corporate development efforts.”